Welcome to the e-CCO Library!

P340 Comorbidity is associated with safety outcomes in vedolizumab- and ustekinumab-treated inflammatory bowel disease patients
Year: 2020
Source: ECCO'20 Vienna
Authors: V. Asscher1, V. Biemans2,3, M. Pierik3, G. Dijkstra4, A. Van der Meulen-de Jong1, M. Löwenberg5, S. van der Marel6, N. de Boer7, A. Bodelier8, J. Jansen9, R. West10, J. Haans3, W. van Dop2, R. Weersma4, F. Hoentjen2, J. Maljaars1, on behalf of the Dutch Initiative on Crohn and Colitis (ICC)
Created: Thursday, 30 January 2020, 10:12 AM
Last Modified: Thursday, 24 February 2022, 4:23 PM by Dietrich Diz Angerer-GTN
P340: Issues on implementing treat-to-target approach in Asia Pacific, Middle East and Africa: Reality, gaps, and way forward -APMA IBD Coalition
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Akyüz, F.(1)*;An, Y.K.(2);Aniwan, S.(3);Bui, H.H.(4);Chan, W.P.(5);Choi, C.H.(6);Chopdat, N.(7);Connor, S.(8);Desai, D.(9);Flanagan, E.(10);Kobayashi, T.(11);Leong, R.W.(12);Leow, A.(13);Leung, W.K.(14);Limsrivilai, J.(15);Peddi, K.(16);Pribadi, R.R.(17);Ran, Z.(18);Wei, S.C.(19);Wu, K.(20);Ye, B.D.(21);
Created: Friday, 14 July 2023, 11:05 AM
P340: Postoperative clinical recurrence in Crohn’s disease patients: the Practicrohn study
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

E. Domènech*1, V. García2, M. D. Martín Arranz3, M. Barreiro-de Acosta4, A. Gutiérrez5, L. Cea-Calvo6, C. Romero6, B. Juliá6

Created: Friday, 22 February 2019, 9:49 AM
P340: Prevalence and long-term effect of antiplatelet use in inflammatory bowel disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Mantaka A., Renieri V., Koutroubakis I.

Created: Wednesday, 20 February 2019, 10:36 AM
P340: Real-world treatment patterns and recurrence rates of rectovaginal fistulas in patients with Crohn’s disease: A retrospective cohort database analysis
Year: 2021
Source: ECCO'21 Virtual
Authors: Karki, C.(1);Latremouille-Viau, D.(2);Gilaberte, I.(3);Hantsbarger, G.(4);Romdhani, H.(2);Lightner, A.(5);
Created: Wednesday, 2 June 2021, 4:12 PM
P340: Risankizumab in Inflammatory Bowel Disease: Real World Experience from a Pre-Approval Access Program
Year: 2021
Source: ECCO'22
Authors: Dawson, P.(1);Sharma, E.(1);Dart, R.J.(1);Lim, S.(1);Anderson, S.H.(1);Ray, S.(1);Mawdsley, J.(1);Irving, P.M.(1);Samaan, M.A.(1);
Created: Friday, 11 February 2022, 3:52 PM
Last Modified: Friday, 4 March 2022, 1:42 PM by Dietrich Diz Angerer-GTN
P340: Serum albumin and C-reactive protein week 2/week 0 ratio after anti-TNF therapy best predict both short- and long-term clinical outcomes in anti-TNF-naïve ulcerative colitis patients
Year: 2018
Source: ECCO '18 Vienna
Authors:

S.-H. Lee1*, K. Chang1, E.M. Song1, S.W. Hwang1,2, S.H. Park1,2, D.-H. Yang1, J.-S. Byeon1, S.-J. Myung1, S.-K. Yang1,2, B.D. Ye1,2

Created: Thursday, 21 February 2019, 9:14 AM
P340: Vedolizumab in the treatment of chronic refractory pouchitis: a systematic review
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

W-C. Lim*1, H. Lin1

Created: Friday, 22 February 2019, 9:41 AM
P341 Induction of response and remission: a network meta-analysis of induction studies comparing ontamalimab with other treatments for moderate-to-severe ulcerative colitis
Year: 2020
Source:

ECCO'20 Vienna

Authors:

A. Vickers1, A. Nag2, B. Devine3, B.E. Sands4, R. Panaccione5, L. Peyrin-Biroulet6, S. Danese7, S. Vermeire8, K.J. Gorelick9, M. Goetsch10, L. Hartley1

Created: Thursday, 30 January 2020, 10:12 AM
P341: Analytical performance of a new iPhone-based patient monitoring system comparable to ELISA for measuring faecal calprotectin in inflammatory bowel disease patients
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

K. F. Wintgens*1, A. A. Wulandari2, A. Dignass3, 4, F. Hartmann3, 4, J. Stein2, 3

Created: Friday, 22 February 2019, 9:49 AM
P341: Combination of corticosteroids and 5-aminosalycilates or corticosteroids alone for patients with moderate-severe active ulcerative colitis: a global survey of physicians' practice
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Ben-Horin S.*1,2, Andrews J.M.3, Katsanos K.H.4, Rieder F.5, Steinwurz F.6, Karmiris K.7, Cheon J.H.8, Moran G.W.9, Cesarini M.10, Stone C.D.11, Schwartz D.12, Protic M.13, Roblin X.14, Roda G.15, Chen M.2, Har-Noy O.1, Bernstein C.N.16

Created: Wednesday, 20 February 2019, 10:36 AM
P341: Faecal biomarkers compared with MRI using the MaRIA and Clermont scores for monitoring inflammatory activity in patients with Crohn’s disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

J. Langhorst1*, A. Koch1, J. Boone2, A. Rueffer3, G. Dobos4, L. Umutlu5, Y. Li5

Created: Thursday, 21 February 2019, 9:14 AM
P341: Fracture risk in middle-age and older patients with inflammatory bowel disease: A Korean nationwide population-based cohort study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Ji Min, L.(1)*;Lee, K.M.(2);Han, K.D.(3);
Created: Friday, 14 July 2023, 11:05 AM
P341: Identification and management of psychological distress after stoma surgery: a qualitative study of patients and healthcare professionals
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

K. Polidano*1, C. A. Chew-Graham1,2,3, A. D. Farmer4,5, B. Saunders1

Created: Friday, 22 February 2019, 9:41 AM
P341: Perceived risks and psychosocial burden during the COVID-19 pandemic in a large cohort of pediatric and adult patients with Inflammatory Bowel Disease
Year: 2021
Source: ECCO'21 Virtual
Authors: Koletzko, L.(1);Klucker, E.(2);Le Thi, G.(2);Breiteneicher, S.(1);Rubio-Acero, R.(3);Neuhaus, L.(1);Stark, R.(4);Standl, M.(5);Hölscher, M.(3);Török, H.(1);Koletzko, S.(2,6);Schwerd, T.(2);
Created: Wednesday, 2 June 2021, 4:12 PM
P341: Pharmacokinetics and exposure-response analyses of upadacitinib in patients with moderate to severe ulcerative colitis – Analyses of induction and maintenance clinical trials
Year: 2022
Source: ECCO'22
Authors: Ponce-Bobadilla, A.V.(1);Stodtmann, S.(1);Eckert, D.(1);Zhou, W.(2);Liu, W.(2);Mohamed, M.E.(2);
Created: Friday, 11 February 2022, 3:52 PM
P342 Diagnostic accuracy of rectal bleeding and stool frequency in predicting mucosal healing in patients with ulcerative colitis in the tofacitinib OCTAVE Phase 3 induction studies
Year: 2020
Source:

ECCO'20 Vienna

Authors:

J.F. Colombel1, A.G. Bushmakin2, J.C. Cappelleri2, N. Kulisek3, G.O. Santana4, N. Lawendy3, D. Ponce de Leon5, P.L. Lakatos6

Created: Thursday, 30 January 2020, 10:12 AM
P342: A population pharmacokinetic model to support therapeutic drug monitoring during vedolizumab therapy
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

E. Dreesen*1, B. Verstockt2,3, S. Vermeire2,3, M. Ferrante2,3, A. Gils1

Created: Friday, 22 February 2019, 9:41 AM
P342: Correlation of the first lateral flow-based Point of Care test to quantify infliximab and anti-infliximab antibodies in a finger prick sample with the reference ELISA technique
Year: 2021
Source: ECCO'21 Virtual
Authors: Ruiz-Argüello, M.B.(1);Pascual, J.(1);Del Río, L.(1);Urigoitia, A.(1);Balo Farto, C.(2);Fernández, C.(3);Mera, A.(2);De Toro, J.(3);Nagore, D.(1);Ametzazurra, A.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P342: Development of self-screening tool for perianal disease in patients with Crohn’s disease: A pilot study
Year: 2018
Source: ECCO '18 Vienna
Authors:

E.S. Kim1, B.I. Jang2*, H.S. Lee1, Y.J. Lee3, E.Y. Kim4, K.O. Kim2, K.H. Song5, S.K. Kim1, Crohn's and Colitis Association in Daegu-Gyeongbuk (CCAiD)

Created: Thursday, 21 February 2019, 9:14 AM